MAZELSKY JONATHAN JAY sold $17.7M of IDXX

MAZELSKY JONATHAN JAY (Executive Chair of the Board) sold 25,140 shares of IDEXX LABORATORIES INC /DE (IDXX) at an average of $703.19 ($698.26–$711.95, $17.68M total) across 13 trades on 2026-11-04.

Original reporting
SEC EDGAR · MAZELSKY JONATHAN JAY
Published Nov 5, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IDXX
Bearish
medium confidence
Mentioned
$IDXX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IDXXBearishLow
01

Why it matters

The disclosed sale is the first public report of this transaction, making it a primary source of new information.

02

Market read

Insider sell of $17.7 M may trigger short interest and price dip in IDEXX.

03

What to watch

No 10b5‑1 plan; the timing may be unrelated to company fundamentals.

Relevance 6/10Novelty 6/10Timing: post‑market filing

Background

Form 4 filings disclose insider transactions; large sales by executives often attract trader attention.

Company-level read

Ticker impact

$IDXXBearishMedium confidence
Context

Executive Chair Jonathan Jay Mazelsky sold 25,140 shares of IDEXX Laboratories for $17.7 M, reducing his stake to 83,803 shares.

Expected impact

likely downward pressure as the market prices in the insider sell.

Evidence & confidence

A $17.7 M open‑market sale by a top insider is material and new, suggesting potential concerns.

Market effects

May prompt scrutiny of other biotech insiders' holdings.

Limited to U.S. biotech sector.

Low; primarily affects IDEXX shareholders.

Counterpoint

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Jonathan Jay Mazelsky

    Executive Chair of IDEXX Laboratories

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IDXXHighAI 8/10

IDEXX Laboratories Inc (IDXX) (Q3 2026) Earnings Call Highlights: Raised Outlook

IDEXX Laboratories reported Q3 2026 earnings, raising its full-year organic growth outlook to nearly 10% despite challenges. US clinic visits declined 1.8%, and macro pressures impacted puppy/kitten adoptions. CoVet acquisition is expected to dilute EPS by $0.13 in 2026. Global Rapid Assay revenues grew 1% organically. The company attributed growth to innovations, record instrument placements, and higher-quality visits.